• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Cel-Sci Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    5/19/25 4:15:38 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CVM alert in real time by email
    cvm_8k.htm
    0000725363false00007253632025-05-192025-05-19iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (date of earliest event reported):  May 19, 2025

     

    CEL-SCI CORPORATION

    (Exact name of Registrant as specified in its charter)

     

    Colorado

     

    001-11889

     

    84-0916344

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File No.)

     

    (IRS Employer

    Identification No.)

     

    8229 Boone Blvd., #802

    Vienna, VA 22182

    (Address of principal executive offices, including Zip Code)

     

    Registrant’s telephone number, including area code:(703) 506-9460

     

    N/A

    (Former name or former address if changed since last report)

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)

     

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

     

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14c))

     

    Title of each class

     

    Trading Symbol(s)

     

    Name of each exchange on which registered

    Common Stock

     

    CVM

     

    NYSE American

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§203.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§204.12b-2 of this chapter.

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ 

     

     

     

     

    Item 5.07. Submission of Matters to a Vote of Securities Holders.

     

    The annual meeting of CEL-SCI’s shareholders was held on May 19, 2025. At the meeting the following persons were elected as directors for the upcoming year:

     

     

    Name

     

    Votes For

     

    Votes Against

     

    Broker Non-Votes

     

    Geert Kersten

     

    21,571,997

     

    4,878,281

     

    18,092,130

     

    Bruno Baillavoine

     

    16,278,124

     

    10,172,154

     

    18,092,130

     

    Robert Watson

     

    16,672,564

     

    9,777,714

     

    18,092,130

     

    At the meeting the following were approved by CEL-SCI’s shareholders:

     

     

    (2)

    the adoption of CEL-SCI’s 2025 Non-Qualified Stock Option Plan; and

     

     

     

     

    (3)

    the adoption of CEL-SCI’s 2025 Stock Bonus Plan; and

     

     

     

     

    (4)

    the combination of CEL-SCI’s common stock; and

     

     

     

     

    (5)

    the appointment of BDO USA, P.C. as CEL-SCI’s independent registered public accounting firm for the fiscal year ending September 30, 2025.

     

    The following is a tabulation of votes cast with respect to proposals 2 through 5:

     

     

    Proposal

     

    Votes For

     

    Votes Against

     

    Abstain

     

    Broker Non-Votes

     

    (2)

     

    18,096,468

     

    8,088,876

     

    264,934

     

    18,092,130

     

    (3)

     

    17,857,852

     

    8,208,995

     

    383,431

     

    18,092,130

     

    (4)

     

    28,279,258

     

    15,613,723

     

    649,427

     

    -

     

    (5)

     

    40,219,973

     

    3,543,525

     

    778,910

     

    -

     

     

    2

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     Date:  May 19, 2025 

    CEL-SCI CORPORATION

     

     

     

     

     

     

    By:

    /s/Geert Kersten

     

     

     

    Geert Kersten

     

     

     

    Chief Executive Officer

     

      

     

    3

     

    Get the next $CVM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CVM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CVM
    SEC Filings

    See more
    • Cel-Sci Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - CEL SCI CORP (0000725363) (Filer)

      7/14/25 4:25:11 PM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Cel-Sci Corporation

      424B5 - CEL SCI CORP (0000725363) (Filer)

      7/11/25 6:31:07 PM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by Cel-Sci Corporation

      S-3 - CEL SCI CORP (0000725363) (Filer)

      7/3/25 4:09:10 PM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Talor Eyal was granted 1,048 shares, increasing direct ownership by 23% to 5,548 units (SEC Form 4)

      4 - CEL SCI CORP (0000725363) (Issuer)

      7/1/25 9:29:35 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Prichep Patricia B was granted 1,873 shares, increasing direct ownership by 21% to 10,747 units (SEC Form 4)

      4 - CEL SCI CORP (0000725363) (Issuer)

      7/1/25 9:26:19 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Kersten Geert R was granted 2,292 shares, increasing direct ownership by 6% to 43,638 units (SEC Form 4)

      4 - CEL SCI CORP (0000725363) (Issuer)

      7/1/25 9:22:49 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Watson Robert Eugene bought $27,800 worth of shares (20,000 units at $1.39), increasing direct ownership by 451% to 24,431 units (SEC Form 4)

      4 - CEL SCI CORP (0000725363) (Issuer)

      5/10/24 9:04:18 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Prichep Patricia B bought $11,120 worth of shares (8,000 units at $1.39), increasing direct ownership by 4% to 232,326 units (SEC Form 4)

      4 - CEL SCI CORP (0000725363) (Issuer)

      5/9/24 1:07:10 PM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kersten Geert R bought $41,700 worth of shares (30,000 units at $1.39), increasing direct ownership by 3% to 1,195,309 units (SEC Form 4)

      4 - CEL SCI CORP (0000725363) (Issuer)

      5/9/24 9:19:04 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CVM
    Leadership Updates

    Live Leadership Updates

    See more
    • CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

      CEL-SCI Corporation (NYSE:CVM) today reported financial results for the quarter ended June 30, 2024, as well as key recent clinical and corporate developments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815767286/en/The table includes detailed results from the bias analysis. (Graphic: Business Wire) Clinical and Corporate Developments include: In July 2024, following the end of the third fiscal quarter, CEL-SCI reported the results of a bias analysis. The bias analysis, a standard process to ensure a trial's findings are reliable, was conducted in preparation for CEL-SCI's upcoming confirmatory Registration Study. This

      8/15/24 8:00:00 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEL-SCI Appoints Robert Watson as Chairperson of the Board

      CEL-SCI Corporation (NYSE:CVM) today announced that Robert ("Bob") Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital formation strategies and partnerships to drive an efficient capital structure. During his career as CEO or President of private and publicly traded companies in the healthcare sector, Bob negotiated over a half dozen exits and more than $750 million in capital transactions including IPOs, secondary offerings, and debt in

      7/8/24 9:15:00 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEL-SCI Appoints Mario Gobbo to Its Board of Directors

      CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as investment banking and strategic advisory services. He has served as an officer or director for a number of companies including several biotech companies: Xcovery, Ocimum/Genelogic and Helix BioPharma. Prior to that, Mr. Gobbo worked in the financial industry for Lazard LLC, Swiss Bank Corporation, the European Bank for Reconstruction and Development, Natixis Bleichroeder, Inc., and International Finance Corporation

      4/23/24 9:00:00 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CVM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

      CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were approximately $5.7 million. The Company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate purposes, and working capital. ThinkEquity acted as the sole placement agent for the offer

      7/14/25 4:05:00 PM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

      CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock is being sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $5.7 million. The offering is expected to close on July 14, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to fund the continued developmen

      7/11/25 12:16:00 PM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

      Strong interest from Saudi investment funds in CEL-SCI, Multikine, and potential joint venture to address the wider Middle East and North Africa market Patient access and reimbursement/sale in Saudi Arabia within approximately 60 days following filing for Breakthrough Medicine Designation CEL-SCI Corporation (NYSE:CVM) today announced it has reached an agreement with one of Saudi Arabia's premier pharmaceutical and healthcare companies for a partnership that spans regulatory and commercial activities for Multikine* (Leukocyte Interleukin, Injection) in the Kingdom of Saudia Arabia. The formal agreement is expected to be signed with the Saudi pharmaceutical partner which will file a Brea

      7/11/25 9:15:00 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

      SC 13G/A - CEL SCI CORP (0000725363) (Subject)

      2/8/23 10:48:28 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

      SC 13G/A - CEL SCI CORP (0000725363) (Subject)

      4/11/22 1:55:14 PM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

      SC 13G/A - CEL SCI CORP (0000725363) (Subject)

      2/11/22 7:53:04 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care